Viewing Study NCT01882933


Ignite Creation Date: 2025-12-25 @ 3:02 AM
Ignite Modification Date: 2026-01-28 @ 7:33 PM
Study NCT ID: NCT01882933
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2024-05-08
First Post: 2013-06-13
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: D2 Resection and HIPEC (Hyperthermic Intraperitoneal Chemoperfusion) in Locally Advanced Gastric Carcinoma
Sponsor: Hospices Civils de Lyon
Organization:

Study Overview

Official Title: GASTRICHIP : D2 Resection and HIPEC (Hyperthermic Intraperitoneal Chemoperfusion) in Locally Advanced Gastric Carcinoma. A Randomized and Multicentric Phase III Study.
Status: ACTIVE_NOT_RECRUITING
Status Verified Date: 2024-05
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: GASTRICHIP
Brief Summary: A prospective, opened, multicentric, randomised, phase III trial with two arms:

* Arm A: curative gastrectomy with D1-D2 lymph node dissection + HIPEC with oxaliplatin
* Arm B: curative gastrectomy with D1-D2 lymph node dissection

Main objective: Compare overall 5-year survival rates in patients surgically treated for advanced gastric adenocarcinoma (T3, T4 and/or N+ and/or with positive peritoneal cytology), treated either with curative gastrectomy and adjuvant HIPEC, or with curative gastrectomy alone.
Detailed Description: None

Study Oversight

Has Oversight DMC: True
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: